Nagaki M, Shimizu M, Sugihara JI, Tomita E, Sano C, Naiki T, et al. Clinical trial: extended treatment duration of peginterferon- alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders. Aliment Pharmacol Ther. 2009;30(4):343-51....
which was initiated in July 2020 as a 4-year trial comprising two substudies, one of which is A3, and the other one is A45. A3 is enrolling 400 people whose amyloid levels are below the brain-wide threshold
[17] ANTONIOTTI C, ROSSINI D, PIETRANTONIO F, et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, ...
作者: Enrollment is underway in a Phase 1/2b clinical trial evaluatingArcutisBiotherapeutics (ARQT -2.4%) ARQ-252 in adult patients with eczema (atopic dermatitis) on their hands. The Phase 2b portion should launch in H2 with topline data expected in H2 2021. ARQ-252 is a topical cream ...
An unanticipated problem was encountered, check back soon and try again Error Code: MEDIA_ERR_UNKNOWN Session ID: 2025-03-23:b14e51fec431e19142b31a6f Player Element ID: vjs_video_3 OK 共享 Tableau: What does Tableau mean to your team of clinical trial consultants? Jeff Epstein, CEO: It...
成人接种重组戊型肝炎疫苗的长期效果:一项随机、双盲、安慰剂对照、Ⅲ期试验的10年结果 ②The Lancet:Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial ...
What’s happening at Clario? Discover how Clario is driving innovation in clinical trial endpoint technology. See all news Clario Enters into Definitive Agreement to Acquire WCG’s eCOA Business March 10, 2025Read more MEDIA COVERAGE Lauren Misztal interviewed about responsible use of AI ...
et al. Paclitaxel with inhibitor of apoptosis antagonist, LCL161, for localized triple-negative breast cancer, prospectively stratified by gene signature in a biomarker-driven neoadjuvant trial. J. Clin. Oncol. 36, 3126–3133 (2018). Article CAS Google Scholar Isaacs, J. S., Xu, W. & ...
[18] DAMATO A, IACHETTA F, ANTONUZZO L, et al. Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR tr...
CureVac. CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV https://www.curevac.com/en/2021/06/16/curevac-provides-update-on-phase-2b-3-trial-of-first-generation-covid-19-vaccine-candidate-cvncov/ (2021). Cohen, J. What went wrong with Cur...